Japan Earnings Highlights: Takeda, Astellas And Eisai
This article was originally published in PharmAsia News
Takeda preps for cost-cutting program; Astellas clears path for Xtandi; and Eisai leans on Belviq in the U.S. with aggressive coverage program.
You may also be interested in...
Phase III ELM-PC 5 study of orteronel in post-chemo metastatic castration-resistant prostate cancer is unblinded after drug fails to improve overall survival. But the company is continuing a Phase III trial in an earlier line of therapy.
European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation
German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.
Two events lead the way to greater coverage and reimbursement for obesity drugs: a bipartisan, bicameral bill that would remove Medicare Part D’s ban on covering obesity drugs and AMA’s recognition of obesity as a disease.